GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Debt-to-Equity

Instituto Rosenbusch (BUE:ROSE) Debt-to-Equity : 0.31 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch Debt-to-Equity?

Instituto Rosenbusch's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ARS441 Mil. Instituto Rosenbusch's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ARS562 Mil. Instituto Rosenbusch's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ARS3,235 Mil. Instituto Rosenbusch's debt to equity for the quarter that ended in Mar. 2024 was 0.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Instituto Rosenbusch's Debt-to-Equity or its related term are showing as below:

BUE:ROSE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.3   Med: 0.64   Max: 1.19
Current: 0.54

During the past 13 years, the highest Debt-to-Equity Ratio of Instituto Rosenbusch was 1.19. The lowest was 0.30. And the median was 0.64.

BUE:ROSE's Debt-to-Equity is ranked worse than
67.49% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.295 vs BUE:ROSE: 0.54

Instituto Rosenbusch Debt-to-Equity Historical Data

The historical data trend for Instituto Rosenbusch's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instituto Rosenbusch Debt-to-Equity Chart

Instituto Rosenbusch Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 1.19 1.08 0.95 0.54

Instituto Rosenbusch Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 1.04 0.65 0.54 0.31

Competitive Comparison of Instituto Rosenbusch's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instituto Rosenbusch's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Debt-to-Equity falls into.


Instituto Rosenbusch Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Instituto Rosenbusch's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(435.763 + 598.084) / 1914.478
=0.54

Instituto Rosenbusch's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(441.035 + 562.345) / 3235.086
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch  (BUE:ROSE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Instituto Rosenbusch Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Instituto Rosenbusch (BUE:ROSE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Debt-to-Equity
Comparable Companies
BSP:ARXD11 BSP:DMVF3 BSP:SNCI11 BSP:NUTR3 BSP:JOPA3 BSP:HUCG11 BSP:DTCY3 BSP:FATN11 BSP:DVFF11 BSP:BMIN3 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Website
https://www.rosenbusch.com
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.